Authors
Latest:
Lenalidomide Maintenance Prolongs PFS in Elderly DLBCLFor the first time, a study shows that using an immunomodulatory agent as maintenance therapy prolongs progression-free survival for patients with diffuse large B-cell lymphoma after first-line treatment with rituximab plus CHOP.
Latest:
Combination agents target early, late stages of allergyOphthalmic drops that combine immediate antihistamine relief with prophylactic care in the form of mast cell inhibition and eosinophil blockage are the mainstay of therapy for allergic conjunctivitis.
Latest:
Combination agents target early, late stages of allergyOphthalmic drops that combine immediate antihistamine relief with prophylactic care in the form of mast cell inhibition and eosinophil blockage are the mainstay of therapy for allergic conjunctivitis.
Latest:
Leveling Up: Cell Therapy Research Expands Horizons in Autoimmune DiseaseCell therapy, particularly CAR-T, is expanding into autoimmune diseases like lupus and multiple sclerosis. While promising, safety, efficacy, and broad applicability remain uncertain.
Latest:
Merit Cudkowicz, MD, on Evaluating Mesenchymal Cell Therapy for ALSBrainStorm Cell Therapeutics has decided to submit a BLA for NurOwn in ALS following an erratum to a phase 3 trial.
Latest:
Research on CAR T Therapy in Earlier Lines of TreatmentAmit Patel, BSc, MBBS, PhD, discusses currently ongoing clinical trials of CAR T-cell therapy in first- and second-line treatment settings and comments on potential developments on the horizon.
Latest:
Phase 2 Study of Combo Therapy Shows Promise for Patients With Mantle Cell LymphomaA phase 2 trial demonstrated that the regimen of rituximab, bortezomib, bendamustine, and dexamethasone is a viable treatment option for older patients with mantle cell lymphoma (MCL), and highlighted the usefulness of using minimal residual disease (MRD) to guide early and late clinical decisions.
Latest:
CAR-T Cells: The Next Era in Immuno-OncologyAn update on immunotherapies and the potential impact of chimeric antigen receptor (CAR)-T cells on oncology care.
Latest:
CAR-T Cells: The Next Era in Immuno-OncologyAn update on immunotherapies and the potential impact of chimeric antigen receptor (CAR)-T cells on oncology care.
Latest:
The Potential Impact of CAR T-Cell Treatment Delays on SocietyTreatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Latest:
The Potential Impact of CAR T-Cell Treatment Delays on SocietyTreatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Latest:
The Potential Impact of CAR T-Cell Treatment Delays on SocietyTreatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Latest:
The Potential Impact of CAR T-Cell Treatment Delays on SocietyTreatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Latest:
The Potential Impact of CAR T-Cell Treatment Delays on SocietyTreatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Latest:
Targeting Leptomeningeal Brain Tumors With CAR T TherapyManuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio, discussed upcoming research on MB-101 cell therapy.
Latest:
Potential of NK Cells in Multiple Myeloma: Nina Shah, MDThe hematologist and oncologist from UCSF Helen Diller Family Comprehensive Cancer Center discussed the potential utility of natural killer cells in multiple myeloma.
Latest:
Dr. Pagel on the Utility of CAR T-Cell Therapy in Relapsed/Refractory DLBCLJohn M. Pagel, MD, PhD, discusses the utility of CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Latest:
Michael Wang, MD, on Liso-Cel's Approval in Mantle Cell LymphomaThe professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center discussed the advantages the newly approved CAR-T has for older, frailer patients.
Latest:
Dr. Shaughnessy on Addressing Challenges With CAR T-Cell Therapy in Hematologic MalignanciesPaul J. Shaughnessy, MD, discusses the challenges faced with CAR T-cell therapy in hematologic malignancies.
Latest:
Dr. Frigault on Toxicity Differences Among CAR T-Cell Products in Leukemias, LymphomasMatthew Frigault, MD, discusses differences in the toxicities experienced with CAR T-cell products used in the treatment of patients with leukemias and lymphomas.
Latest:
CAR T-Cell Therapy Transforms Leukemia and Lymphoma Treatment, But Toxicity Concerns RemainOlalekan O. Oluwole, MBBS, MD, discusses the approvals of tisagenlecleucel and axicabtagene ciloleucel, along with several research efforts that have been dedicated to the development and exploration of CAR T-cell therapies in the realm of leukemias and lymphomas.
Latest:
Dr. Tzachanis on the Likelihood of Cure With CAR T-Cell Therapy in LymphomaDimitrios Tzachanis, MD, PhD, discusses the likelihood of cure with CAR-T cell therapy in lymphoma.
Latest:
CAR T Pioneers Describe Challenges Faced in CancerAdvances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.
Latest:
Nilanjan Ghosh, MD, PhD, on Paving the Way for CAR T Therapies in LymphomasThe chief of the lymphoma division and oncologist at Levine Cancer Institute discussed work that needs to be done to support the use of CAR T therapy.
Latest:
Dr. Vesole on Developing Off-the-Shelf CAR T-Cell Therapy in Multiple MyelomaDavid H. Vesole, MD, PhD, discusses the importance of developing off-the-shelf CAR T-cell therapy products in multiple myeloma.
Latest:
Noopur Raje, MD, on bb21217 Data in R/R Multiple MyelomaThe director, Center for Multiple Myeloma, Massachusetts General Hospital, discussed data seen with bb21217 in R/R MM.
Latest:
Back to the Bench: Exploring the Potential of CAR T-Cell Therapy in OncologyMiguel-Angel Perales, MD, and Caron A. Jacobson, MD, share insights regarding the context and implications of the recent actions by the FDA to add boxed warnings to CAR T-cell therapies.
Latest:
TILs, the Ultimate in Personalized Immunotherapy, Move Closer to MarketNovember 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.
Latest:
Making Progress Against Relapsed/ Refractory DLBCL Without CAR TA panel of lymphoma experts discuss several novel agents for relapsed/ refractory diffuse large B-cell lymphoma, some of which have been recently approved.
